Akums Drugs and Pharmaceuticals Limited has announced its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The company reported a profit before tax of ₹1,031.84 million for the six-month period, with total comprehensive income of ₹774.76 million for the same period. Additionally, Mr. Sanjay Kumar has been designated as Senior Management Personnel.
Financial Highlights for Q2 FY27
Akums Drugs and Pharmaceuticals Limited has disclosed its unaudited standalone financial results for the quarter and six months ended September 30, 2026. The company reported a profit before tax of ₹1,031.84 million for the six-month period, a notable increase compared to the previous year’s period. Total comprehensive income for the six-month period stood at ₹774.76 million.
For the quarter ended September 30, 2026, the standalone profit before tax was ₹438.48 million, with total comprehensive income of ₹313.04 million. The standalone revenue from operations for the quarter was ₹3,950.47 million.
Consolidated Performance
On a consolidated basis, the company reported a profit before tax of ₹2,155.43 million for the six-month period ended September 30, 2026. The consolidated total comprehensive income for the same period was ₹2,149.31 million. For the quarter, the consolidated profit before tax was ₹656.73 million, with total comprehensive income at ₹383.93 million. The consolidated revenue from operations for the quarter was ₹10,724.48 million.
Key Personnel Update
In a significant update, Mr. Sanjay Kumar has been designated as Senior Management Personnel, holding the position of President – Operations. This designation was approved by the Board of Directors based on the recommendation of the Nomination & Remuneration Committee. His appointment is effective from November 02, 2026, and he has a full-time employment term as per the company’s policy. Mr. Kumar brings over 27 years of experience in manufacturing and operations within the pharmaceutical sector.
Deviation in Fund Utilisation
The company also provided a statement on the deviation/variation in the utilisation of funds raised through public issues. As per the filing, the original objects of raising funds included repayment of indebtedness, funding working capital, and pursuing inorganic growth. The company stated that there have been no deviations or variations in the utilisation of funds raised through the Initial Public Offer (IPO) for the stated objects, except for adjustments in allocation for General Corporate Purposes (GCP) and inorganic growth initiatives. The amount utilised for general corporate purposes does not exceed 25% of the Gross Proceeds.
Source: BSE
